CSBRHIGH SIGNALFINANCIAL10-K

CSBR achieved a dramatic turnaround from -$7.3M net loss to $4.7M profit while expanding data licensing capabilities and growing revenue 14% to $56.9M.

This represents a remarkable operational transformation, with the company achieving profitability while simultaneously strengthening its balance sheet and cash position. The removal of previous impairment language and addition of new data licensing revenue streams suggests CSBR has successfully repositioned its business model for sustainable growth.

Comparing 2025-07-23 vs 2024-07-19View on EDGAR →
FINANCIAL ANALYSIS

CSBR delivered exceptional financial improvements across all key metrics, with net income swinging from -$7.3M loss to $4.7M profit and operating cash flow surging from -$6.1M to positive $7.4M. The company strengthened its balance sheet significantly, with stockholders' equity turning positive at $3.8M and cash reserves growing nearly 4x to $3.2M, while total assets expanded 24% to $32.3M. Most notably, CSBR achieved this turnaround while reducing R&D expenses by 28% and cutting capital expenditures in half, demonstrating improved operational efficiency and disciplined capital allocation.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+298.2%
-$1.9M$3.8M

Equity base grew 298.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+278.2%
$856K$3.2M

Cash position surged 278.2% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
+220.4%
-$6.1M$7.4M

Operating cash flow surged 220.4% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+164.6%
-$7.3M$4.7M

Net income grew 164.6% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+161.9%
-$7.4M$4.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
+64%
$13.6M$22.4M

Current assets grew 64% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-53.5%
$836K$389K

Capex reduced 53.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
-28.5%
$9.5M$6.8M

R&D spending cut 28.5% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
+23.8%
$26.1M$32.3M

Asset base grew 23.8% — expansion through organic growth, acquisitions, or capital deployment.

Accounts Receivable
Balance Sheet
+17.9%
$9.5M$11.2M

Receivables grew 17.9% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2025-07-23
PRIOR — 2024-07-19
ADDED
Data Licenses We offer access to certain PDX model data via licensing agreements.
As our platform has been expanded over time with the collection of models and the enhancement of their characterization, we have developed a robust multi-omic dataset with substantial potential for both drug discovery and development.
This dataset serves as a vital resource for both our pharmaceutical and biotechnology customer who gain access to model-specific data and further their research via licensed access.
Software As A Service (SaaS) Business Our SaaS business is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains comprehensive information derived from our research services and clinical studies and is sold to customers on an annual subscription basis.
For the fiscal year ended April 30, 2025, revenues from our products and services totaled approximately $56.9 million, an increase of approximately 14% from the previous year.
+7 more — sign up free →
REMOVED
Software As A Service (SaaS) Business Our SaaS business, launched during the fiscal year ended April 30, 2021, is centered around our proprietary software platform and data tool, Lumin Bioinformatics ("Lumin"), which contains comprehensive information derived from our research services and clinical studies and is sold to customers on an annual subscription basis.
During the fiscal year ended April 30, 2023, we recorded an impairment charge for the capitalized software development costs of Lumin related to return on investment guidelines.
However, we continue to maintain the Lumin platform and sell subscriptions as part of our product offerings as the Lumin data is an integral part of the Company s long term strategy and value proposition.
For the fiscal year ended April 30, 2024, revenues from our products and services totaled approximately $50.1 million, a decrease of approximately 7% from the previous year.
The global oncology drug market is estimated to be as high as $223 billion in 2023.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →